GLAND PHARMA Q2 FY27 CONCALL: MAINTAINS 15% FY27 CONSTANT-CURRENCY REVENUE GROWTH GUIDANCE; PLANS ₹3,000 CR CAPEX PLUS VIZAG GREENFIELD PROJECT, CENEXI PROFITABILITY RECOVERY EXPECTED FROM Q3 FY27